Clinical Trials Logo

Verruca clinical trials

View clinical trials related to Verruca.

Filter by:
  • None
  • Page 1

NCT ID: NCT04738734 Completed - Warts Clinical Trials

CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts

Start date: February 16, 2021
Phase: N/A
Study type: Interventional

This prospective, multicenter, single-blinded, randomized comparison study is designed to compare the safety and effectiveness of the CellFX System to Cryosurgery for the clearance of cutaneous non-genital common warts on all areas of the body excluding the scalp, nose, within the orbital region of the face, plantar or periungual area in healthy adult subjects.

NCT ID: NCT04554394 Completed - Warts Clinical Trials

CellFX System for the Treatment of Cutaneous Non-Genital Warts

Start date: July 17, 2019
Phase: N/A
Study type: Interventional

This prospective, non-randomized, multicenter pivotal study is designed to evaluate the safety and effectiveness of the CellFX System in patients with cutaneous non-genital warts on all areas of the body, excluding the face.

NCT ID: NCT03487549 Completed - Virus Diseases Clinical Trials

Cantharidin and Occlusion in Verruca Epithelium

COVE-1
Start date: March 27, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase 2, open label study (Study number VP-102-105; referred to as COVE-1 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy, safety and tolerability of VP-102 treatment in subjects with common warts. This study has two Cohorts.

NCT ID: NCT01536834 Completed - Plantar Wart Clinical Trials

Safety & Performance Study of Verruca Treatment Device

Start date: June 2012
Phase: N/A
Study type: Interventional

This is a non comparative pre-CE marking pilot clinical investigation is required to evaluate the safety and performance in intended use of the Verruca treatment - NPD396, Class IIa medical device for verrucas in the adult population. The treatment regime will be topical application of the Verruca treatment to the verruca, identified as the reference, once daily for 4 weeks. Patient & investigator derived outcomes will also be collected to assess clinical performance and adverse events and adverse device effects will be reported to assess safety profile. Patient assessments will take place pre-treatment to determine patient demography, baseline clinical status, pain and verruca size prior to treatment. Compliance with treatment schedule will be collected via patient diary cards. Furthermore, patients will be assessed on day 2 after starting treatment and then again at 7, 14, 21 & 28 days after starting treatment. Diary cards will completed through-out the investigation.